Clinical Trial Update: A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis [Phase 1]

View source ↗

Summary

This is a Phase 1 trial of subcutaneously administered tocilizumab for systemic juvenile idiopathic arthritis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Juvenile Idiopathic Arthritis | Phase 1 | Status: COMPLETED